Stock & Company Details
Mirum Pharmaceuticals Inc $MIRM
Price:
N/A
N/A
65M
$5.3B
52 Week High:
N/A
10 Day Average Volume:
N/A
-5.59
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
MIRM technical indicators
Latest Mirum Pharmaceuticals Inc (MIRM) indicator readings as of 2026-10-09.
MIRM's 14-day RSI is 42.2, in neutral territory. At $86.01 it is trading 12.7% below its 200-day moving average of $98.47, and below its 50-day average of $95.18. Price sits in the middle of its Bollinger Bands ($77.09 to $99.60). ADX reads 39.2, indicating a trending market.
MIRM backtested strategy results
How 4 rule-based strategies performed on Mirum Pharmaceuticals Inc (MIRM) over recent history, last backtested 2026-09-06. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +118.6% | 80% | 5 | -31.7% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +22.6% | 30% | 33 | -64.0% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +72.5% | 40% | 30 | -44.7% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +98.3% | 73% | 11 | -18.2% |
Overview
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Finance Bot
Ask your questions
Start by typing a question below.
